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Growing evidence suggests that Parkinson’s disease is not solely affecting the dopaminergic sys-
tem. Results from biochemical, animal, postmortem, and functional imaging studies have revealed
that other neurotransmitter systems are affected as well, including the serotonergic system. With
the use of in vivo positron emission tomography functional imaging, it has been shown that
serotonergic terminals are affected at a varying, nonlinear degree starting early in the clinical
course of Parkinson’s disease. Tremor and the majority of nonmotor symptoms do not seem
to respond adequately to dopaminergic medication. Recent studies suggest that serotonergic
dysfunction has a direct relevance to Parkinson’s disease symptoms, the so-called nonmotor
symptoms, including depression, fatigue, weight changes, and visual hallucinations. These in vivo
ﬁndingsindicate that agentsacting on the serotonergicsystemcould help towards alleviating these
symptoms. This paper aims to review the current literature and to highlight the need for further in
vivo investigations.
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1. INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative disorder of the elderly and is clinically charac-
terized by the motor symptoms of tremor, bradykinesia, and rigidity. The pathological hallmark of PD in-
volves the presence of Lewy bodies, resulting in the degeneration of dopamine (DA) neurons in substantia
nigra pars compacta (SNc) and subsequently, the striatum. According to Braak’s staging of Lewy body
deposition [1], the pathological process begins in the dorsal motor nucleus, proceeding in an ascending
fashion to the midbrain (including caudal raphe nuclei) and forebrain.
However, growing lines of evidence suggest that PD is not solely a DA-ergic disease but that there
is a more diffuse pathology involving other, non-DA neurotransmitter systems, such as the serotonergic.
Serotonin (5-HT) neurons in the dorsal raphe nuclei project mainly to the basal ganglia, particularly the
striatum, but also to the frontal cortex and the limbic system. The serotonergic system is thought to be
involved in the modulation of various cognitive and physiological processes, such as, mood, emotion,
sleep, and appetite; thus altered serotonergic neurotransmission is likely to be implicated in both motor
and nonmotor disturbances observed in PD [2]. Both motor and nonmotor symptoms are troublesome for
patients and affect their quality of life. A recent study outlined the most troublesome symptoms for PD
patients following self-report assessments [3], and it was found that both early and advanced PD patients
consider tremor, depression, and problems with appetite, weight, and visual hallucinations in their top ten
most bothersome symptoms.
Postmortem, animal, and functional imaging studies [4–8] have demonstrated serotonergic dysfunc-
tion in PD. The use of functional imaging techniques, such as positron emission tomography (PET) and
single-photonemission computed tomography(SPECT) allows the investigationof 5-HT neuronal integrity
across the clinical course of PD and also allows the investigation of correlations between imaging and
clinical data.
2. STAGING OF SEROTONERGIC DYSFUNCTION IN PARKINSON’S DISEASE
Functionalimaginghasbeenimplementedto assessthe integrity of theserotonergicterminals in PD andhas
usedtheavailability ofthe5-HT transporter(SERT)asanindex.However,functionalimaginginvestigations
of SERT have resulted in contradictory data due to the use of radiotracers not speciﬁct oSER T( 123I-β-CIT)
[6, 9, 10] or with high nonspeciﬁcbinding (11C-McN5652) [6] making it difﬁcult to measure SERT binding
in brain regions of low serotonergic innervation. 123I-β-CIT is a SPECT ligand with afﬁnity for the DA
transporter (DAT), norepinephrine transporter (NAT), and SERT. Also, 11C-McN5652 PET has relatively
high nonspeciﬁcbinding for SERT in regions of low to moderate SERT density. 11C-DASB currently offers
the best selective marker for SERT with high speciﬁcity and sensitivity for SERT (nanomolar afﬁnity) and
al o wa f ﬁnity for DAT and NAT (micromolar afﬁnity) [11]. Therefore, it is likely that 11C-DASB binding
reﬂects the functional loss of SERT in SERT-expressing terminals due to the denervation of serotonergic
pathways.However,despite the ability of current radiotracerstomeasure5-HTreceptors andSERT,without
the knowledge of which cells the 5-HT receptors or SERT are on, interpretation of results can be viewed in
a number of ways.
A decrease of striatal 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) has been
detected in postmortem PD brains [5]. However, striatal hyperinnervation has been observed in a recent PD
postmortem study [12] and animal models of PD [13]. These ﬁndings may be reﬂective of a compensatory
mechanism due to the loss of striatal DA as it has been demonstrated that 5-HT neurons are able to
convert L-DOPA to DA, although in an unregulated manner [14], with recent animal studies providing
evidenceof oversprouting5-HT neurons[15, 16]. Therefore, this phenomenonshouldbe taken into account
when interpreting functional imaging ﬁndings considering that the majority of PD patient entering these
studies will be undergoing L-DOPA therapy. However, for all studies reviewed here, the patients will have
withdrawn from L-DOPAtherapyfor at least12–18hours prior to scanning,resulting in patients undergoing
scanning in the practically deﬁned “OFF” condition.
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11C-DASB has been used in two preliminary studies [7, 8]. Guttman et al. [7], studied nine clinically
advanced nondepressed PD patients (mean disease duration 12 years) and 13 healthy controls. It was
reported that PD patients displayed an overall decrease in SERT binding levels (between 7–30%) with
signiﬁcant decreases in orbitofrontal cortex (22%), caudate (30%), putamen (26%), and midbrain (29%).
This study presented evidence advancing the knowledge from previous postmortem and neuroimaging
studies by demonstrating that a decrease in SERT binding cannot solely be an end-stage phenomenon in
PD. Albin et al. [8] studied ﬁve non-depressedPD patients (H&Y staging between 1–2.5) and eight healthy
controls. This study reported symmetrically reduced SERT binding throughout the forebrain and brainstem
of PD patients. The greatest reductions of 11C-DASB binding were observed in the cingulate cortex and
insula (40–50%) followed by the amygdala, hippocampus,thalamus, basal ganglia, rostral brainstem nuclei
(30–35%), and caudal brainstem structures (−20%). This was the ﬁrst study to consider the caudal brain
stem regions in relation to serotonergic denervation in PD and demonstrated symmetrical rather than
asymmetrical binding reductions as usually demonstrated nigrostriatal terminal markers. It is important to
note that these preliminary studies did not account for any other nonmotor symptoms in their patients such
as fatigue, sleep, or appetite problems which may have inﬂuenced the ﬁndings. Furthermore, neither study
addressed the effect of chronic exposure to DA replacement therapy (DRT) (either as mono- or polytherapy
with DA agonists and/or L-DOPA) on SERT binding as this may inﬂuence the SERT availability [17].
A recent study from our group using in vivo 11C-DASB PET as a marker of presynaptic serotonergic
terminal integrity aimed to assess the serotonergic dysfunction in early (0–5 years disease duration),
established (5–10 years), and advanced (more than 10 years of PD) PD patients [18]. This study reported
global reductions of presynaptic serotonergic terminals, which did not correlate with disease duration or
motor disability. For the ﬁrst time, this study addressed the question whether chronic exposure to DRT
inﬂuences5-HT terminal functioning; no correlation was found in any of the examinedbrain regions.It was
demonstrated that early PD patients displayed reduced 11C-DASB in the caudate, thalamus, hypothalamus,
and anterior cingulate cortex. PD patients with established disease showed additional reductions in the
putamen, insula, posterior cingulate cortex, and prefrontal cortex. Advanced PD patients had further
reductionsin the ventralstriatum, raphenucleiandamygdala.Furthermore,it wasdemonstratedthatthereis
a preferential loss of SERT in the caudate (early = 28.2%, established = 29.8%, advanced = 34.4%) versus
the putamen (early = 13.3%, established = 23.0%, advanced = 30.0%) in all stages of PD studied. This
is consistent with an earlier postmortem study showing a preferential loss of 5-HT markers in the caudate
versusthe putamen(−56% versus−30%) [5]. DA dysfunctionin the caudateseemsto be comparableto the
serotonergic dysfunction (−40%) found by Politis et al. [18] but attenuated, compared to DA dysfunction
found in the putamen (70–80%) with 18F-DOPA PET [19]. The authors conclude that there is a nonlinear
loss of SERT in the PD brain across the course of the disease, which is not related to disease duration,
disability, or DRT [18].
The results from this study suggest that the pattern of serotonergic denervation is different to that
observed in the DA system. 18F-DOPA and 18F-CFT have detected greater reductions in the posterior
putamen, which inversely correlates with disease progression [20–22] and differs from 11C-DASB where
the putamen appears to be affected later. Braak et al. [1] suggest that the pathological process of PD begins
in the dorsal motor nucleus and progresses in an ascending fashion with midbrain and forebrain structures
affected later. At stage 2 of this process, Lewy body and neurite deposition occur within the raphe nuclei
with the substantia nigra, amygdala, and hypothalamus affected at stage 3. According to this hypothesis,
caudal serotonergic brainstem neurons are affected prior to DA-ergic midbrain neurons. However, the in
vivo PET data [18] suggest that there is a relative preservation of caudal and rostral raphe nuclei until a
later stage of the disease process. Thus far, there is little knowledge regarding the density and functional
effect of Lewy body and neurite deposition in the serotonergic neurons. It is possible that alpha-synuclein
accumulates in 5-HT neurons at an early stage but the effect is less toxic than in DA neurons.
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3. SEROTONERGIC DYSFUNCTION AND PARKINSON’S
DISEASE SYMPTOMATOLOGY
3.1. Tremor
Tremor is one of the most challenging symptoms to manage in the parkinsonian patient with a poorer
responseto DA-ergic therapycomparedto bradykinesiaandrigidity [23]. It is likely thatasystemotherthan
the DA-ergic may play a role in its pathophysiology. In this context, both animal and functional imaging
studieshavefailedto revealanycorrelationbetweendenervationoftheDA-ergic systemandtremor. Brooks
et al. [24] and Asenbaum et al. [25] utilising 18F-DOPA PET and 123I-β-CIT SPECT, respectively, have
demonstrated that reductions in striatal DA terminal function correlate with the severity of bradykinesia
and rigidity but not with tremor.
Resting tremor can be evoked in primates by lesioning the midbrain tegmentum [26]. Such lesions
interrupt the serotonergic and noradrenergic projections, thus possibly accounting for the development of
tremor in the primates. In this animal study, it was observed that 5-HT levels were reduced ipsilateral to the
lesion in the brainstem and that tremor and bradykinesia manifested contralateral to the lesion.
To date, only one PET imaging study has been conducted to investigate the association between
tremor and dysfunction in the 5-HT system in 26 PD patients and eight healthy controls using 11C-WAY-
100635 PET, a selective marker of 5-HT1A receptors [27]. It was demonstrated that midbrain raphe 5-
HT1A binding was reduced by 27% in PD patients compared to healthy controls. The authors also report
a correlation between reduction of midbrain raphe 5-HT1A binding and severity of tremor as measured
by the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) but not rigidity or bradykinesia. The authors
suggest that the reductions in 5-HT1A binding could reﬂect loss of 5-HT neuronal cell bodies, likely due to
Lewy body pathology. However, further in vivo studies are required to explore the inﬂuence of serotonergic
dysfunction in tremorgenesis.
3.2. Depression
DepressioninPDisoneofthemostcommonnonmotorsymptomsanditisestimatedtoaffectapproximately
40–50% of patients [28, 29]. Clinically identifying depressive symptomatology in PD is a challenging
process because several features of depression overlap with PD symptomatology.
11C-RTI 32 PET is a marker of both DAT and NAT bindings. A study using this PET technique
showed reduced putaminal 11C-RTI 32 uptake in PD patients without a history of depression. PD patients
with a history of depression (but antidepressant-free for at least three months) demonstrated additional
reductions in the locus coeruleus,thalamus, and the limbic system (amygdala, ventral striatum, and anterior
cingulate) [30]. Measures of anxiety severity also inversely correlated with 11C-RTI 32 binding in these
regions. The DA-ergic system is shown to be less affected in the ventral striatum compared to more dorsal
regions in PD, although it receives most of the noradrenergic afferents from the striatum [31]. Therefore,
these ﬁndings indicate that the noradrenergic system may be implicated in depression in PD.
However, 11C-RTI 32 has a very low afﬁnity for SERT and therefore, cannot assess the serotonergic
system. 123I-β-CIT SPECT in non-PD depressed patients has shown increased uptake in the striatum com-
pared to healthy controls [32]. There have been a few attempts to investigate, in vivo, serotonergic in-
volvement in the pathophysiology of depression in PD. Doder et al. [33]u s e d11C-WAY-100635 PET in a
pilot study of PD patients with and without depression and healthy controls. Although the authors reported
a decrease in midbrain raphe 5-HT1A receptor binding in the PD patients compared to healthy controls,
there were no differences between depressed and nondepressed PD patients.
Another study utilizing the nonspeciﬁcm a r k e rf o rS E R T ,123I-β-CIT SPECT, studied seven PD
patients with depressive symptoms as measured by the Hamilton Depression Rating Scale (HDRS), who
were not receiving any antidepressant medications. The authors reported no differences in midbrain 123I-β-
CIT binding comparedto healthycontrols andnocorrelation between 123I-β-CIT binding andHDRS scores
in the PD with depression group [9].
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11C-DASB PET has been utilised in a pilot study of seven early-stage PD patients (mean disease
duration 4 years) with current depressive disorder as classiﬁed by the structured clinical interview DSM-
IV Axis I Disorders (SCID-I) who did not receive antidepressant medication [34]. This study reported an
overallincreaseinextrastriatalSERTbindingrangingbetween8–68%with speciﬁcincreasesin dorsolateral
(37%) and prefrontal (68%) cortices compared to a group of sevenhealthy controls. Correlating 11C-DASB
binding with depression symptom severity as measured by the Hamilton Depression Scale (HDS-21) was
signiﬁcant only for the orbitofrontal cortex.
Recently, our group used 11C-DASB PET and a larger cohort of 34 antidepressant-na¨ ıve PD pa-
tients and 10 age- and sex-matched healthy controls in order to investigate associations between in vivo
serotonergic dysfunction and depressive symptomatology [35]. All participants were assessed using the
Beck Depression Inventory-II (BDI-II), HRSD, and the SCID-I. It was demonstrated that PD patients
with depressive symptoms had signiﬁcantly increased 11C-DASB binding in the amygdala, hypothalamus,
caudal raphe nuclei, and posterior cingulate cortex compared to matched-PD patients without depressive
symptomatology but not compared to healthy controls. The 11C-DASB binding increases in these regions
in the PD group with depression correlated with depressive symptomatology. The ﬁndings from this study
suggest that relatively increased SERT binding in raphe and limbic regions is implicated in PD depression
possiblydue to a combinedloss of 5-HT terminals andupregulationof SERT function in these regions.This
provides evidence for the use of agents acting on SERT for the treatment of PD depression.
3.3. Weight Alterations
PD patients characteristically lose body mass index (BMI) [36], a phenomenon observed among 52–65%
of patients. It has been suggested that weight loss in PD patients occurs as a continuous process starting
several years prior to diagnosis [37]. Conversely, weight gain has been observed in PD patients on L-
DOPA and following deep brain stimulation (DBS) [38]. Appetite regulation has been associated with the
serotonergic system [39], and functional imaging studies in non-PD individuals with high BMI have dem-
onstrated decreased cerebral SERT binding as measured with 11C-DASB PET [40].
There is only one study to date which has investigated in vivo the relationship between BMI changes
and serotonergic dysfunction in PD [41]. This study calculated BMI changes over a 12-month period and
compared 11C-DASB binding in PD patients with normal and abnormal BMI alterations, and a group of
healthy controls with stable BMI. The results showed that PD patients with abnormal BMI alterations had
an increase of SERT binding in raphe nuclei, caudate, hypothalamus, and ventral striatum compared to PD
patients without abnormal BMI alterations. The 11C-DASB binding increases in these regions correlated
with BMI alterations in the PD group with abnormal BMI changes over the 12-month period. Moreover,
PD patients who gained BMI demonstrated raised SERT availability in the anterior cingulate cortex (ACC).
The authors suggest that lower levels of 5-HT resulting from an increased clearance in the synapse, in an
otherwiseaffected5-HT system,couldplaya primary role in the pathophysiologyofﬂuctuating BMI in PD.
3.4. Fatigue
It is estimated that approximately one third of PD patients experiencedisabling fatigue [42]. Studies of non-
PD patients with chronic fatigue syndrome have demonstrated that the serotonergic system may contribute
to its pathophysiology [43].
Serotonergic transmissionin PD patientswith fatigue hasbeeninvestigatedin a combined 18F-DOPA
and 11C-DASB PET study [44]. This study investigated 20 PD patients; 10 with fatigue and 10 without
fatigue. Results showed that PD patients with fatigue had a signiﬁcant reduction of 11C-DASB binding in
the putamen (−83%), caudate nucleus (76%), ventral striatum (−74%), and thalamus (−66%), and also the
cingulateandamygdalacomparedto thePD patientswithoutfatigue.Due to basalgangliareceivingsensory
and motor input from cortical regions, the authors suggest that their result of reduced SERT expression
supports the pathophysiological model that a disruption of the neurotransmitter balance within the basal
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ganglia and associated regions inﬂuences the integration of emotional and motor information in limbic re-
gions, thus resulting in fatigue symptoms.
3.5. Visual Hallucinations
Visual hallucinations are reported to occur up to approximately 60% of PD patients [45]. Reduction of
DA medication dose does not always attenuate visual hallucinations, and no correlation has been shown
so far between visual hallucinations and DA medication type or dose. Therefore, it is likely that visual
hallucinations in PD are not purely drug-induced and may be due to a neuropathological dysfunction
affecting terminals other than DA monoaminergic terminals such as the 5-HT.
A recent PET study utilising 18F-setoperone, a marker for 5-HT2A receptors availability, compared
seven PD patients with visual hallucinations and seven PD patients without visual hallucinations [46]. It
was reported that PD patients with visual hallucinations had increased 5-HT2A binding in ventral visual
pathway, dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. These regions have been
associated with typical aspects of visual hallucinations in PD, such as objective and subjective perception
and recognition [47, 48] and the phenomenology of complex nonstationary scenarios [49, 50]. Thus, the
authors suggest that their ﬁndings provide justiﬁcation for the use of selective 5-HT2A receptor antagonists
in the treatment of visual hallucinations in PD.
4. CONCLUSIONS
In vivo evidence from functional imaging studies suggests that the recently demonstrated serotonergic dys-
function in PD is related to tremor, depressive symptomatology, weight and appetite problems, fatigue, and
visual hallucinations. The degeneration of serotonergic terminals is a process that starts early in the course
of PD, however, it does not follow the extent nor the linearity of the degeneration observed in the DA-ergic
system. Alterations in the serotonergic system may be a contributing factor to PD symptomatology and in
particular, the nonmotor symptoms observedin PD. Further research should carefully delineate correlations
between clinical data and serotonergic dysfunction in order to elucidate the underling mechanisms of these
symptoms, thus providing vital information regarding novel interventions for their management.
ABBREVIATIONS
PET: Positron emission tomography
SPECT: Single-photon emission computed tomography
5-HT: Serotonin; 5-hydroxytryptamine
SERT: Serotonin transporter
PD: Parkinson’s disease
DA: Dopamine
DA-ergic: Dopaminergic
SNc: Substantia nigra pars compacta
18F-DOPA: Fluorine-18-L-dihydroxyphenylalanine
123I-β-CIT: [123I]-2b-carbomethoxy-3b-(4-iodophenyl)tropane
L-DOPA: levodopa
DBS: Deep brain stimulation.
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